⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLUE News
Monte Rosa Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
globenewswire.com
GLUE
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
globenewswire.com
GLUE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
GLUE
Gluware Named Finalist in Two Categories of SiliconANGLE Media's 2026 Tech Innovation CUBEd Awards
prnewswire.com
GLUE
NOW
NMRK
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
globenewswire.com
GLUE
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
GLUE